Sirtuins and Cancer

The wide spectrum of biological activities exhibited by the sirtuins linking transcriptional repression and activation, metabolic state and stress response strongly 

An endogenous SI RTl modulator and several targets have been described that hint at potential therapeutic benefits from pharmacological SIRTl inhibition in a number of cancer models. The gene product of deleted in breast cancer 1 (DBCl) interacts with and inhibits SIRTl [95, 96]. Dovmregulation of DBCl expression in normal 

Together these findings predict a major role for sirtuin modulators, both activators and inhibitors, in the treatment of cancer. 

---